BCR–ABL1 mRNA levels represent the key molecular marker for the evaluation of minimal residual disease (MRD) in chronic myeloid leukemia (CML) patients and real-time quantitative PCR (RT-qPCR) is currently the standard method to monitor it. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.